Shots:

• The US FDA has approved Verzenio + ET for the adjuvant treatment of adult patients with HR+- HER2-- node-positive- EBC at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test
• The approval is based on subgroup analyses of P-III monarchE trial with additional follow-up- conducted post-hoc. In this analysis- Verzenio + ET demonstrated a 37% reduction in the risk of BC recurrence or death vs ET alone for patients with benefits in IDFS event rate of 7.1% @3yrs.
• IDFS events (104 vs 158). Verzenio is the first addition to adjuvant endocrine therapy approved by the FDA in nearly two decades for the treatment of HR+ HER2- EBC

  Ref: PR Newswire | Image: Eli Lilly